Shanshan Y. Chen

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Efficacy and safety of neoadjuvant radiotherapy in patients with resectable hepatocellular carcinoma

Efficacy and safety of neoadjuvant radiotherapy in patients with resectable hepatocellular carcinoma

Journal: Zhonghua yi xue za zhi

Published: September 07, 2026

Learning journeys and identity transformation of foreign undergraduate nursing students in China: a journey mapping study.

Learning journeys and identity transformation of foreign undergraduate nursing students in China: a journey mapping study.

Journal: BMC medical education

Published: May 10, 2026

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

Journal: Thoracic cancer

Published: April 12, 2026

Association between low-density lipoprotein cholesterol and frailty in adults aged ≥70 years: a cross-sectional study from Beijing, China.

Association between low-density lipoprotein cholesterol and frailty in adults aged ≥70 years: a cross-sectional study from Beijing, China.

Journal: Frontiers in endocrinology

Published: January 16, 2026

Understanding undergraduate nursing students' learning journeys with artificial intelligence: a journey mapping study.

Understanding undergraduate nursing students' learning journeys with artificial intelligence: a journey mapping study.

Journal: BMC medical education

Published: January 07, 2026

Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.

Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.

Journal: Breast cancer research : BCR

Published: October 27, 2025

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial.

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial.

Journal: Cancer letters

Published: August 27, 2025

Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.

Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.

Journal: Therapeutic advances in medical oncology

Published: August 12, 2025

6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation.

6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation.

Journal: Neuron

Published: August 05, 2025

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.

Journal: Therapeutic advances in medical oncology

Published: July 22, 2025

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.

Journal: Future oncology (London, England)

Published: July 21, 2025

Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.

Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.

Journal: Breast cancer research and treatment

Published: July 11, 2025

Showing 1-12 of 85

Last Updated: 09/26/2026